Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Viemed Healthcare (VMD) Shares Repurchased (2018 - 2026)

Viemed Healthcare posted quarterly Shares Repurchased of $1.4 million for Q1 2026, down 87.55% on a QoQ basis from $11.6 million in Q3 2025.

Viemed Healthcare (VMD) has 5 years of Shares Repurchased data on file, last reported at $1.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Shares Repurchased changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $14.7 million (changed N/A YoY), and the FY2025 full-year result was $13.2 million, changed N/A from the prior year.
  • Shares Repurchased for Q1 2026 stood at $1.4 million, down from $11.6 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $11.6 million in Q3 2025 and bottomed at $710000.0 in Q4 2022.
  • The 3-year median for Shares Repurchased is $1.9 million (2022), against an average of $3.5 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 Viemed Healthcare 373.53 Mn 365.70 Mn 42.83 Mn 1.44 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.44 Mn
Mar 31, 2026 1.44 Mn
Sep 30, 2025 11.56 Mn
Sep 30, 2025 11.56 Mn
Jun 30, 2025 1.66 Mn
Jun 30, 2025 1.66 Mn
Dec 31, 2022 710,000.00
Dec 31, 2022 710,000.00
Sep 30, 2022 1.86 Mn
Sep 30, 2022 1.86 Mn
Jun 30, 2022 5.11 Mn
Jun 30, 2022 5.11 Mn
Mar 31, 2022 1.89 Mn
Mar 31, 2022 1.89 Mn
Mar 31, 2019 1.52 Mn
Mar 31, 2019 1.52 Mn
Dec 31, 2018 1.59 Mn
Dec 31, 2018 1.59 Mn